Allarity TherapeuticsALLR -0.77%24 PS Ratio is 58.64 as of Jun. 30, 2026, which is 1% below its 10-year median of 59.09. GuruFocus rates ALLR with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 935 Biotechnology companies, Allarity Therapeutics ranks worse than 79.89% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Allarity Therapeutics's share price is $1.29.
Allarity Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02. Hence, Allarity Therapeutics's PS Ratio for today is 58.64.
The historical rank and industry rank for Allarity Therapeutics's PS Ratio or its related term are showing as below:
ALLR'
s PS Ratio Range Over the Past 10 Years
Min: 41.54 Med: 59.09 Max: 80.45
Current: 58.66
During the past 7 years, Allarity Therapeutics's highest PS Ratio was 80.45. The lowest was 41.54. And the median was 59.09.
ALLR's PS Ratio is ranked worse than 79.89% of 935
companies
in the Biotechnology industry
Industry Median: 9.37
vs ALLR: 58.66
Allarity Therapeutics (NAS:ALLR) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Allarity Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allarity Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Allarity Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Allarity Therapeutics's Share Price of today is $1.29. Allarity Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Allarity Therapeutics (ALLR) has a PS Ratio of 58.64 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Allarity Therapeutics and its competitors. This is near median its historical median of 59.09. Over the past decade, Allarity Therapeutics' PS Ratio has ranged from 41.54 to 80.45. According to the industry distribution chart, Allarity Therapeutics ranks #747 out of 935 companies in the Biotechnology industry, placing it in the top 79.9%.
Is Allarity Therapeutics' PS Ratio too high?
Allarity Therapeutics' current PS Ratio of 58.64 is near median its 10-year median of 59.09. Over the past 10 years, this metric has ranged from a low of 41.54 to a high of 80.45. The Biotechnology industry median PS Ratio is 9.37. Allarity Therapeutics' value of 58.64 is 525.8% above this industry median. Based on the distribution chart, Allarity Therapeutics ranks #747 out of 935 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Allarity Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' PS Ratio compare to NCEL and LPCN?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #747 out of 935 companies for PS Ratio. This places Allarity Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.37. Allarity Therapeutics' value of 58.64 is 525.8% above this benchmark. Historically, Allarity Therapeutics' own PS Ratio has ranged from 41.54 to 80.45 over the past decade. While the company's 10-year median is 59.09 vs. the industry median of 9.37, Allarity Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.37, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allarity Therapeutics's current PS Ratio of 58.64 is 525.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Allarity Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allarity Therapeutics's current PS Ratio is 58.64, which is near median its own 10-year median of 59.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current PS Ratio of 58.64. The current PS Ratio is 58.64, which is near median its 10-year median of 59.09 and 525.8% above the Biotechnology industry median of 9.37. Allarity Therapeutics' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current PS Ratio is 58.64 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
24GF Score
Get the complete analysis for ALLR
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALLR has been successfully added to your 
